(CercleFinance.com) – Novo Nordisk announces the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).
Since 2015, their scientists have co-invented new devices that deliver drugs orally. This collaboration resulted in the SOMA robotic pill, which was then licensed exclusively to Novo Nordisk for clinical development.
The new agreement extends the collaboration through 2026, broadening the scope to encompass the creation and integration of bioelectronic devices, biosensors and stimulus-responsive delivery devices.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
